TAILORx Update: 12-Year Recurrence and Survival Outcomes for Patients With Early-Stage Breast Cancer
Joseph Sparano, MD, discusses original research at the San Antonio Breast Cancer Symposium finding that patients with hormone receptor-positive, HER2-negative, intermediate-risk, early breast cancer can receive adjuvant endocrine therapy alone without increasing their risk of late recurrence.